MedTrace Logo

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

NCT05079425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-02-08

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo- controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

NXC736

Oral administration

DRUG

Placebo

Oral administration

Sponsors & Collaborators

  • NEXTGEN Bioscience

    lead INDUSTRY

Principal Investigators

  • Seungwhan Lee · Seoul National University College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079425 on ClinicalTrials.gov